

## **COVID-19 IN CANCER PATIENTS**

### **Abstract**

Severe acute respiratory syndrome (SARS-CoV-2) spread in whole of the world and was declared as pandemic by the WHO [world health organization]. SARS-CoV-2 has been responsible to cause more severe symptoms in immunocompromised patients. Much effort is currently being put into researching COVID-19's pathophysiology and treatment, although there are various parameters which are not very well known to us; reasons are still unknown. The purpose of the review is to encourage research into prognoses of COVID-19 infections in cancer patients, allowing for better clinical management of these patients. These researches will further help professionals to get the exact prognosis and help treat patients. These all features which will be mentioned in the article will show impact of covid on patients with various type of cancer. There are various risks associated with cancer during corona as these people are having very less immunity. Diseases which are very communicable easily infect people with cancer. There is no difference in symptoms seen in normal person and immunocompromised patients. The main motive is to help doctors in assessing prognosis and treatment.

**Keywords:** Covid 19, Anticancer Treatment, Sars-Cov-2, Immunosuppressed Patients, Treatment

### **Introduction**

Severe acute respiratory syndrome (SARS-COV-2) caused by novel coronavirus, has spread over the world, causing the COVID-19 pandemic [1]. Fever, myalgia, and exhaustion are the most common COVID-19 symptoms, with headaches, haemoptysis, and septum formation as secondary signs[2]. Active cancer should be considered as a factor that may increase vulnerability due to the immunocompromised state it can cause. The difficulty arises because cancer patients already have significantly compromised and change in immunity as a conclusion of specific cancer therapy, primary illness origin, disease extent, putting them at a greater risk. Incidence rates in cancer patients have increased as the pandemic has progressed, indicating a higher proportion of serious disease cases. COVID-19 patients having cancer had a very great risk and more chances of such severe event occurrences than COVID-19 patients without cancer, as said by Liang et al.[3]. Cancer patients accounted for 5.6 percent of case fatalities among COVID-19 patients, according to the Center for Disease Control and Prevention. Immunocompromised patients have a harder time avoiding respiratory virus infections, rendering them more susceptible to COVID-19. For example, viral pneumonia is linked to 19% of deaths in immunocompromised patients, including does of cancer. This finding emphasises the need of assessing COVID-19 infection along with its treatment outcomes in cancer patients. This is focused on clinical and molecular characteristics of corona infection in carcinoma patients in order to spur research for better managing COVID-19-infected cancer patients.

## **Risk and Biology of SARS-CoV-2 infection in cancer patients**

---

The coronavirus particles are organized with long RNA polymers tightly packed into the center of the particle, and surrounded by a protective capsid, which is a lattice of repeated protein molecules referred to as coat or capsid proteins. In coronavirus, these proteins are called nucleocapsid (N). The coronavirus core particle is further surrounded by an outer membrane envelope made of lipids (fats) with proteins inserted. These membranes derive from the cells in which the virus was last assembled but are modified to contain specific viral proteins, including the spike (S), membrane (M), and envelope (E) proteins.[5]. There additionally are 8 helper proteins, comprising of the spike floor glycoprotein (S), little envelope protein (E), and framework protein (M), notwithstanding 4 critical primary proteins. At the point when the living being spreads quick, transforming into pandemic in nature, it have become essential to perceive the manner in which it progressed and custom-made fundamentally in light of the fact that it went up against different hosts and environmental elements. RNA infections are known for their exorbitant transformation. This has been tried to be just about as much as 1,000,000 examples extra than their hosts'. [7]. Nonetheless, phylogenomic test of 3 follows gained from flare-ups in extraordinary parts of the area discovered that they're related. [9]. Malignancy survivors kindled with SARS-CoV-2 developed additional outrageous COVID-19 signs than COVID-19 victims without records of cancer, suggesting that the resistant reconnaissance systems in victims with a records of most tumours probably won't have totally recuperated, following in a debilitated guard towards COVID-19 ailment movement. Beside ailment and cure related contemplations, numerous most tumours victims' prevalent age is each and every other danger component for outrageous COVID-19 infection. 1. Disease victims developed COVID-19 outrageous signs additional quick than individuals who did now presently don't have most tumors, regardless of the seriousness of the infection (middle chance to outrageous occasions: thirteen days versus 43 days) [1]. Taken together, our discoveries show that most malignant growths victims may likewise have a superior COVID-19 danger and a horrendous anticipation. These companion research have sure disadvantages. They had been presently not generally intentionally randomized, and the example length changed into unassuming. Every establishment had a ton of most malignancies sorts, growth stages, and cure choices. Furthermore, while cure options for COVID-19 defilement improve, more established surveys may likewise develop to be out of date. [10] Additionally, there was no evidence that carcinoma patients had the following rate of extreme COVID-19 than the generally population[11]. To check if malignant growth patients procure extra serious COVID-19 manifestations when disease with SARS-CoV-2, extra rigorously arranged preliminaries are required.

### **Clinical features in cancer patients with COVID-19**

---

Fever, dry cough, and weakness were the most widely recognized symptoms in patients having COVID-19, as per a review study[12]. In spite of the fact that COVID-19 patients with non-malignant growth and disease have comparable clinical introductions, weariness and dyspnea indications seem, by all accounts, to be more normal in the latter[12,13,14].

Malignancy patients with Coronavirus experience numerous issues, including respiratory hardships. Sudden respiratory pain conditions are the most predominant entanglement, trailed by pneumonic embolism (7.1%), septic shock, and intense myocardial infarction.

### **Treatment of COVID-19 in cancer patient**

---

There are five types of treatments: -

1. Oxygen therapy for COVID-19 patients
2. Antiviral treatment for COVID-19 patients
3. Immune enhancement for COVID-19 patients
4. Anti-inflammatory for COVID-19 patients
5. Convalescent plasma therapy for COVID-19 patients

Influence of COVID-19 on cancer diagnosis and management

Covids are firmly identified with searing explodes, oxidative pressure, and other pathophysiological irregularities, which can affect infection appraisal and treatment choices. [15,16,17] In general, a survey showed a huge expansion in serum levels of a few threatening development biomarkers in gentle instances of COVID19, contrasted and commonplace control subjects. These infection biomarkers have likewise been reached out in extreme instances of COVID19 [16]. These changes will affect various values of various things such as access and different diagnosis of cancer and we can get various pharmacological aspect to the disease.

To decrease the chance of infections in cancer patients, various identifications and safeguard also be used and various precautions can be taken. Screening endoscopy could also be delayed or cancelled throughout the pandemic [18]. selections relating to surgical intervention throughout this point endure rigorous moral as well as clinical analysis. Except in high alert cases, it's higher to use integrative conferences to assemble accord relating to surgical medical care attributable to the upper risk of SARS-CoV-2 infections. delaying therapy isn't counselled, as a result of cancer progression could also be increased chances of having inflammatory signs which are also seen because of covid 19. There is also a dose reduction of therapy may be thought-about. astonishingly, cancer patients undergoing radiation therapy failed to show the next risk of getting any severe events from COVID-19, [19]. Radiotherapy required to be safely delivered in a very hypo fractionated mode wherever possible, to reduce the amount of visits to treatment centre[20]. One study showed that previous associate degreeti-PD-1 medical care in carcinoma wasn't related to an hyperbolic chances of severity of COVID-19[21].what SARS-CoV-2 viral infection affects the fruitfulness and result of anti-cancer medical care rely upon our current understanding of organic chemistry and pathophysiological mechanism of COVID-19.

### **Lung cancer association with covid**

Lung is the organ primarily affected by covid. Infection or inflammation of lung parenchyma cause pneumonia. Pneumonia is main cause of death in covid . whereas cardiac problems are main reason for death in covid in India. Pneumonia are of two type first is lobar pneumonia and second is lobar bronchopneumonia. Cancer patients are at high risk of developing covid if in contact. There are various type of lung tumours. Classification of lung cancer are small cell cancer , non-small cell cancer and large cell carcinoma . most common lung tumour is metastasis. Squamous cell carcinoma is more in males than in females its associated with smoking and is centrally located. It occurs due to mutation in p53 rb and CDKN2A gene. Paraneoplastic syndrome associated with squamous cell carcinoma which cause

hypercalcemia, infarction of infected people proinflammatory phenomenon is seen and more oriented treatment should be given. A few non-insusceptible balancing treatments are being investigated. Chloroquine and hydroxychloroquine are antimalarial drugs which have shown antiviral impacts against many kinds of infections, in vitro, remembering for HIV. They depend on two recognized components of activity: repressing low pH-subordinate viral section and modifying post-translational alterations of recently blended proteins by impeding glycosylation[22]. In adenocarcinoma, glands are lined by malignant cells. Immunohistochemical marker are TTF-1. Small cell carcinoma are associated with smoking and is seen more in males. It has worst prognosis and genetically seen in p53 and limy gene. Immunohistochemical markers are neuron specific enolase and chronogram . Large cell carcinoma are of present at peripheral location, associated with smoking and gynaecomastia is seen. Clinically presents with cough dyspnoea and haemoptysis. Associated with Horner's syndrome also. Pathogenesis seen in covid is endothelial injury whereas diffuse alveolar damage is seen in h and e stain. Tree bark appearance is seen. There are various obstructive disease in lungs such as pneumoconiosis coal workers pneumoconiosis asbestos. Various patients of covid were having silicosis as their cause of fibrosis of lungs. Most common primary lung tumour is pulmonary hamartoma. Pulmonary hamartoma is solitary and 3 to 4 cm and well circumscribed lesion. On x-ray lung tumour showed coin shaped lesion. Covid is considered as hypersensitivity reaction caused by massive immune cell activation. ICI-actuated pneumonitis, cytokine discharge condition and viral ARDS result from uncontrolled extreme intense irritation. Intense lung injury results from inflammatory monocyte and macrophage enactment in the pneumonic luminal epithelium [23-25]. CT scan has become very popular during covid time. CT scan score of each lobe is seen and lesion in lungs is seen. If score is more than 7 then this is considered as severe in covid. The foundation of these is to diminish superfluous openness, accordingly lessening the danger of transmission. One of drug-prompted pneumonitis seen in these people because of the cause, COVID-19 ought to be precluded. Lung cancer at apex shows composition of sympathetic chain. carcinoid tumour of lung are more common in female . carcinoid tumour of lung arise from Kulchitsky cells. Carcinoid tumour of lung are only 10% of the carcinoid syndrome cases. Clinically this shows flushing, sweating and diarrhea. H and E shows cell are present in nest like. Carcinoid are of two type which are typical and atypical. Atypical are having two to ten mitosis per ten hpf. Atypical carcinoid are having more pleuro and more necrosis. Malignant mesothelium is having risk factor is asbestosis. Malignant mesothelioma is twenty five to forty years. Lung adenocarcinoma is also caused due to asbestos but latent period is just ten to twenty years. Genetically its having p53 mutation and sv-40 virus. H and E stained spindle cells, epithelioid cell and sarcomatous cells and immunohistochemical marker is calretinin positive . Electron microscopy is long slender microvilli or tono filaments. Malignant mesothelioma is done by asbestos exposure for twenty to forty years. Calretinin is positive for malignant mesothelioma. Vimentin is positive for malignant mesothelioma and electron microscopy in malignant mesothelioma shows long slender microvilli. Lung adenocarcinoma doesn't have anything regarding to asbestos. Lung adenocarcinoma is having calretinin negative , these also has vimentin negative as their lung adenocarcinoma. Fibrosing drug diseases are of two type which are idiopathic pulmonary fibrosis also known as usual initial pneumonia and non specific interstitial pneumonia[26-28] . Idiopathic aspiratory fibrosis is moderate interstitial fibrosis. The short point is that it has fibrosis of the lamina propria and causes honeycomb lung. Ambiguous interstitial pneumonia is liked over ordinary interstitial pneumonia. Ambiguous interstitial pneumonia might be identified with the affiliation issue. Cryptogenic pneumonia is known as obstructive bronchitis that causes pneumonia.

---

## Conclusion

The contamination with COVID-19 fundamentally affects disease determination, anticipation, and treatment results. Malignant growth COVID-19 patients had a more unfortunate pattern than COVID-19 non-disease patients, as indicated by contemplates. Different examinations, then again, have found that the rates of SARS-CoV-2 contamination and serious occasions in disease patients aren't altogether more prominent than in everybody. Coronavirus treatment choices' adequacy and security in malignancy patients should likewise be explored further.

Most of papers including malignant growth patients with COVID-19 are associate examinations with a little example size, poor clinical data, huge heterogeneity of growth stages and disease sorts, just as different medicines, and ebb and flow comprehension of the comorbidities is deficient. Various discussion done about lung tumour helps us go to best prognosis. Best prognosis is found then best treatment is given to person. Despite the fact that we attempt to have convenient evaluation of distributed investigations on effect of COVID-19 on malignant growth patients, our decisions might become outdated since more examination on a theme is relied upon to be distributed during the continuous pandemic emergency. We look to bring issues to light of the manifestations, guesses, and therapy choices for COVID-19-positive disease patients, just as empower examination into the strenuous errand of handling COVID-19 and malignancy comorbidities.

## REFERENCES:

1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide of China. *Lancet Oncol.* 2020;2:335–7.
2. Baaron S., emsh Z.A. MES-CoV as an emerging respiratory illness: A review of prevention methods. *Travel Med. Infect. Dis.* Nov. 209;32 .
3. Lang W. Cacer patients in severe acute respiratory syndrome corona virus twoinfection: a nationwide analysis in China. *Lancet Oncol.* 2020;21(3):335–337.
4. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. *JAMA.* 2020;323(13):1239.
5. He Y. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine. *Biochem. Biophys. Res. Commun.* 2004;324(2):773–781.
6. Wu A. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. *Cell Host Microbe.* 2020;27(3):325–328.
7. Pachetti M. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. *J. Transl. Med.* 2020;18(1):1–9.
8. Armijos-Jaramillo V., Yeager J., Muslin C., Perez-Castillo Y. SARS-CoV-2, an evolutionary perspective of interaction with human ACE2 reveals undiscovered amino acids necessary for complex stability. *Evol. Appl.* 2020;13(9):2168–2178
9. Z. Shen et al., “Genomic diversity of SARS-CoV-2 in COVID-19 patients,” pp. 1–27, 2019
10. Barlesi F, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C, et al. Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. *AACR Annual Meeting 2020 Online.* 2020; April 28 abstr. CT403.
11. Vuagnat P, Frelaut M, Ramtohol T, Basse C, Diakite S, Noret A, et al. COVID-19 in breast cancer patients: a cohort at the institute curie hospitals in the Paris area. *Breast Cancer Res.* 2020; 22:55.

12. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. *Ann Oncol.* 2020;31:894–901.
13. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. *Cancer Discov.* 2020; 10:783–91.
14. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. *J Med Virol.* 2020 DOI : 10.1002/jmv.25972.
15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020; 395:497–506.
16. Wei X, Su J, Yang K, Wei J, Wan H, Cao X, et al. Elevations of serum cancer biomarkers correlate with severity of COVID-19. *J Med Virol.* 2020 DOI: 10.1002/jmv.25957.
17. Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. *Nat Rev Clin Oncol.* 2020; 17:268–70.
18. Dockter AG, Angelos GC. Molecular-based alternatives for colorectal cancer screening during the COVID-19 pandemic. *Surg Technol Int.* 2020; 36:143–7.
19. Okwan-Duodu D, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. *Am J Clin Oncol.* 2015; 38:119–25.
20. Nagar H, Formenti SC. Cancer and COVID-19 – potentially deleterious effects of delaying radiotherapy. *Nat Rev Clin Oncol.* 2020; 17:332–4.
21. Ascierto PA. Experience in using oncology drugs in patients with COVID-19. *AACR Annual Meeting 2020 Online.* 2020; April 28 abstr. CT405
22. Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. *Int J Antimicrob Agents* 2007;30:297–308.10.1016/j.ijantimicag.2007.05.015
23. Liu L, Wei Q, Lin Q, et al. . Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. *JCI Insight* 2019;410.1172.
24. Acharya S, Shukla S, Acharya N. Gospels of a pandemic-A metaphysical commentary on the current COVID-19 crisis. <https://doi.org/10.7860/JCDR/2020/44627.13774>.
25. Arora D, Sharma M, Acharya S, Shukla S, Acharya N. India in “Flattening the Curve” of COVID-19 Pandemic-Triumphs and Challenges Thereof. *Journal of Evolution of Medical and Dental Sciences.* 2020 Oct 26;9(43):3252-6. <https://doi.org/10.14260/jemds/2020/713>.
26. Bawiskar N, Andhale A, Hulkoti V, Acharya S, Shukla S. Haematological Manifestations of Covid-19 and Emerging Immunohaematological Therapeutic Strategies. *Journal of Evolution of Medical and Dental Sciences.* 2020 Nov 16;9(46):3489-95. <https://doi.org/10.14260/jemds/2020/763>.
27. Burhani TS, Naqvi WM. Telehealth--A Boon in the Time of COVID 19 Outbreak. *Journal of Evolution of Medical and Dental Sciences.* 2020 Jul 20;9(29):2081-5.<https://doi.org/10.14260/jemds/2020/454>.
28. Butola LK, Ambad R, Kute PK, Jha RK, Shinde AD, DMIMS W. The Pandemic of 21st Century-COVID-19. *Journal of Evolution of Medical and Dental Sciences.* 2020 Sep 28;9(39):2913-9. (September 28, 2020): 2913–18. <https://doi.org/10.14260/jemds/2020/637>.

UNDER PEER REVIEW